Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol

Cancer Letters

Volumn 207, Issue 1, 2004, Pages 37-47

  Pourgholami, Mohammad H ^a   Lu, Ying ^a   Wang, Lisa ^a   Stephens, Ross W ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Clofazimine; Hepatocellular carcinoma; Lipiodol; Novikoff

Indexed keywords

CLOFAZIMINE; IODINATED POPPYSEED OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTESTINE; LIPOPHILICITY; LIVER CELL CARCINOMA; LIVER FUNCTION; LUNG; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; AZO COMPOUNDS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CLOFAZIMINE; COLORING AGENTS; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; IODIZED OIL; LIPID METABOLISM; LIVER NEOPLASMS; RATS; TIME FACTORS;

ANIMALIA;

EID: 1842473041     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.11.019     Document Type: Article

References (35)

1. Lau W.Y. Management of hepatocellular carcinoma. J. R. Coll. Surg. Edinb. 47:2002;389-399.
2. Johnson P.J. Hepatocellular carcinoma: is current therapy really altering outcome? Gut. 51:2002;459-462.
3. Kurth S., Bulian D., Kreft B., Riemenschneider T. Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats. J. Cancer Res. Clin. Oncol. 122:1996;421-426.
4. Matsui O., Kadoya M., Kameyama T., Yoshikawa J., Takashima T., Nakanuma Y., et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 178:1991;493-497.
5. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release. 65:2000;271-284.
6. Konno T., Maeda H., Iwai K., Maki S., Tashiro S., Uchida M., et al. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer. 54:1984;2367-2374.
7. Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer. 66:1990;1897-1903.
8. Iwai K., Maeda H., Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 44:1984;2115-2121.
9. Konno T. Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in lipiodol. Eur. J. Cancer. 28:1992;403-409.
10. Chou F.I., Fang K.C., Chung C., Lui W.Y., Chi C.W., Liu R.S., et al. Lipiodol uptake and retention by human hepatoma cells. Nucl. Med. Biol. 22:1995;379-386.
11. Bhattacharya S., Dhillon A.P., Winslet M.C., Davidson B.R., Shukla N., Gupta S.D., et al. Human liver cancer cells and endothelial cells incorporate iodised oil. Br. J. Cancer. 73:1996;877-881.
12. Tabaru K., Konno T., Oda T., Nagamitsu A., Ishimaru Y., Kitamura N. Treatment of VX2 carcinoma implanted in the liver with arterial and intraperitoneal administration of oily anticancer agents. Cancer Chemother. Pharmacol. 47:2001;149-154.
13. Arbiser J.L., Moschella S.L. Clofazimine: a review of its medical uses and mechanisms of action. J. Am. Acad. Dermatol. 32:1995;241-247.
14. O'Connor R., O'Sullivan J.F., O'Kennedy R. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab. Rev. 27:1995;591-614.
15. Lee S.J., Wegner S.A., McGarigle C.J., Bierer B.E., Antin J.H. Treatment of chronic graft-versus-host disease with clofazimine. Blood. 89:1997;2298-2302.
16. Van Rensburg C.E.J., Van Staden A.M., Anderson R. The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Cancer Res. 53:1993;318-323.
17. Van Rensburg C.E.J., Durandt C., Garlinski P.J., O'Sullivan J.F. Evaluation of the antineoplastic activities of the riminophenazine agents clofazimine and B669 in tumor-bearing rats and mice. Int. J. Oncol. 3:1993;1011-1013.
18. Sri-Pathmanathan R.M., Plumb J.A., Fearon K.C. Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung-cancer cell line in vitro and in vivo. Int. J. Cancer. 56:1994;900-905.
19. Van Rensburg C.E., Anderson R., O'Sullivan J.F. Riminophenazine compounds: pharmacology and anti-neoplastic potential. Crit. Rev. Oncol. Hematol. 25:1997;55-67.
20. Ruff P., Chasen M.R., Long J.E.H., Van Rensburg C.E.J. A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. Ann. Oncol. 9:1998;217-219.
21. Falkson C.I., Falkson G. A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma. Oncology. 57:1999;232-235.
22. Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102:1980;344-352.
23. Macario A.J., Dugan C., Perez-Lloret I.L., Conway de Macario E. Purification of erythroblastic nests. Blood. 57:1981;922-927.
24. D'Arrigo J.S., Ho S.Y., Simon R.H. Detection of experimental rat liver tumors by contrast-assisted ultrasonography. Invest. Radiol. 28:1993;218-222.
25. Anonymous United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition), Br. J. Cancer 77 (1998) 1-10.
26. Carlsson G., Ekelund L., Stigsson L., Hafstrom L. Vascularization and tumour volume estimations of solitary liver tumours in rats. Ann. Chir. Gynaecol. 72:1983;187-191.
27. Jourdan J.L., Akhter J., Bowrey P., Pourgholami M., Morris D.L. Hepatic intra-arterial injection of lipiodol-1,25-dihydroxyvitamin D3 for hepatocellular carcinoma in rats. Anticancer Res. 20:2000;2739-2744.
28. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:1992;493-501.
29. 188Re) glass microspheres. Int. J. Rad. Oncol. Biol. Phys. 44:1999;189-199.
30. Nakajo M., Kobayashi H., Shimabukuro K., Shirono K., Sakata H., Taguchi M., et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J. Nucl. Med. 29:1988;1066-1077. [erratum appears in J. Nucl. Med. November 29(11)(1879)].
31. Anderson R., Smit M.J. Clofazimine and B669 inhibit the proliferative responses and Na+, K(+)-adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism. Biochem. Pharmacol. 46:1993;2029-2038.
32. van Niekerk E., O'Sullivan J.F., Joone G.K., van Rensburg C.E. Tetramethylpiperidine-substituted phenazines inhibit the proliferation of intrinsically multidrug resistant carcinoma cell lines. Invest. New Drugs. 2001;19211-19217.
33. Van Rensburg C.E., Anderson R., Joone G., Myer M.S., O'Sullivan J.F. Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line. Anti-Cancer Drugs. 8:1997;708-713.
34. Van Rensburg C.E.J., Anderson R., Myer M.S., Joone G.K., O'Sullivan J.F. The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in a human lung cancer cell line. Cancer Lett. 85:1994;59-63.
35. Van Rensburg C.E., Joone G.K., O'Sullivan J.F. Clofazimine and B4121 sensitize an intrinsically resistant human colon cancer cell line to P-glycoprotein substrates. Oncol. Rep. 7:2000;193-195.